Navigation Links
Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference
Date:9/29/2011

of OTO-104 (3 mg or 12 mg) or placebo. Patients were monitored over a three-month observation period following injection.  The study's primary objective was the evaluation of the safety and tolerability of OTO-104.  Additionally, the study evaluated various indicators of OTO-104 clinical activity including changes in vertigo, tinnitus, hearing function and patient quality of life.

"Following a meeting with the United States Food and Drug Administration regarding these Phase 1b results and our proposed plans for continued clinical development of OTO-104, we are now in a strong position to move this program forward," said David A. Weber, Ph.D., president and chief executive officer of Otonomy. "Importantly, our upcoming Phase 2 study will include a much greater number of patients and be powered to deliver statistically significant findings with regard to clinical efficacy.  As such, we look forward to the initiation of this study as we seek to establish the therapeutic potential of OTO-104 to help patients suffering from the debilitating symptoms of Meniere's disease."

About OTO-104OTO-104 is a sustained release formulation of the steroid dexamethasone that has been designed for intratympanic (IT) injection into the middle ear for the potential treatment of a broad range of inner ear disorders including vertigo, hearing loss and tinnitus.  OTO-104 is based on Otonomy's proprietary formulation technology which is intended to overcome the limitations associated with the use of unapproved short acting solutions in the ear.  These include limited drug exposure, large variability of delivered dose and the need for multiple IT injections.

About Meniere's DiseaseMeniere's disease is a disorder of the inner ear characterized by acute episodes of vertigo, fluctuations in hearing, tinnitus and aural fullness.  The underlying cause of Meniere's disease is unknown and there are currently no FDA-approved drug treatments. &
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Otonomy Introduces Scientific Advisory Board
2. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
3. Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
4. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
10. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
11. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Nov. 1, 2011 Epitomics, Inc., a California ... received a Notice of Allowance from the United ... for Identifying Differentially Expressed Proteins (application 10/705,109).  The ... expressed proteins in cell samples using libraries of ...
... Nov. 1, 2011 Netsmart Technologies, Inc., a ... human services organizations nationwide, today announced an agreement ... Health (LACDMH) for the provision of a comprehensive ... which will be known as the Integrated Behavioral ...
... 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ... the 20th Annual Credit Suisse Healthcare Conference on Thursday, ... Pacific Time). (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ... be accessible on the Investors page of the Company,s ...
Cached Biology Technology:County of Los Angeles Selects Netsmart to Provide Comprehensive Behavioral Health Information System 2County of Los Angeles Selects Netsmart to Provide Comprehensive Behavioral Health Information System 3
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... only biological material available to identify persons or find next ... these cases, the kits usually employed to carry out DNA ... the DNA is not available, and that which is available ... for identifying persons from these small fragments of DNA. His ...
... RUSTON, La. Louis Reis, a Louisiana Tech University ... recent summa cum laude graduate in electrical engineering and ... been awarded Graduate Research Fellowships from the National Science ... support for the graduate education of individuals who have ...
... helicopter netting operation on February 28, fitted with the collars, ... the animals at a future date through an automated release ... data collected during the migration of the animals between their ... Valley, Lemhi Valley of Idaho, Horse Prairie and the Medicine ...
Cached Biology News:Developing a tool for identification -- even using very degraded DNA samples 2Developing a tool for identification -- even using very degraded DNA samples 3Louisiana Tech University students receive NSF Graduate Research Fellowships 2Wildlife Conservation Society and Idaho Fish and Game track pronghorn by satellite 2
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
RNase Buffer 25 ml...
Anti-HumanLactoferrin...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products: